• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Inventiva S.A.

    5/2/25 4:05:22 PM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IVA alert in real time by email
    6-K 1 tm2513664d1_6k.htm FORM 6-K

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    For the Month of May 2025

     

    Commission File Number: 001-39374

     

    Inventiva S.A.

    (Translation of registrant’s name into English)

     

    50 rue de Dijon

    21121 Daix France

    +33 3 80 44 75 00
    (Address of principal executive office)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

     

    x Form 20-F ¨ Form 40-F

     

     

     

     

     

     

    INCORPORATION BY REFERENCE

     

    The information contained in this report on Form 6-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.

     

    INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

     

    Annual General Meeting

     

    On May 2, 2025, Inventiva S.A. published a notice of meeting (the “Notice”) to the Ordinary and Extraordinary General Meeting (the “General Meeting”). The General Meeting will be held on May 22, 2025 at 9 a.m., at Hôtel Villa M, 24-30, boulevard Pasteur - 75015 Paris, France. A copy of the Notice is furnished as Exhibit 99.1 to this Report on Form 6-K.

     

     

     

     

    EXHIBIT INDEX

     

    Exhibit No.   Description
    99.1   Notice of meeting to the Ordinary and Extraordinary General Meeting.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

      Inventiva S.A.
         
    Date: May 2, 2025 By: /s/ Frédéric Cren
        Name Frédéric Cren
        Title: Chief Executive Officer

     

     

     

    Get the next $IVA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IVA

    DatePrice TargetRatingAnalyst
    2/21/2025$10.00Buy
    TD Cowen
    11/12/2024$3.00Neutral
    UBS
    10/27/2023$12.00Buy
    Canaccord Genuity
    5/31/2023$11.00Buy
    ROTH MKM
    5/19/2023Sell → Buy
    Societe Generale
    3/17/2023$27.00Buy
    Stifel
    11/15/2022Buy → Sell
    Societe Generale
    11/22/2021$40.00 → $42.00Buy
    HC Wainwright & Co.
    More analyst ratings